Microbot Medical (NASDAQ: MBOT) Announces Acceptance of Late-Breaking Abstract for SIR Annual MeetingOn February 4, 2025, Microbot Medical Inc., a developer of the LIBERTY® Endovascular Robotic System, disclosed the acceptance of a late-breaking abst

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Microbot Medical’s 8K filing here.

About Microbot Medical

(Get Free Report)

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.

Read More